Last reviewed · How we verify
Leuprolide Oral Tablet 4-mg BID — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Leuprolide Oral Tablet 4-mg BID (Leuprolide Oral Tablet 4-mg BID) — Enteris BioPharma Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Leuprolide Oral Tablet 4-mg BID TARGET | Leuprolide Oral Tablet 4-mg BID | Enteris BioPharma Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Leuprolide Oral Tablet 4-mg BID CI watch — RSS
- Leuprolide Oral Tablet 4-mg BID CI watch — Atom
- Leuprolide Oral Tablet 4-mg BID CI watch — JSON
- Leuprolide Oral Tablet 4-mg BID alone — RSS
Cite this brief
Drug Landscape (2026). Leuprolide Oral Tablet 4-mg BID — Competitive Intelligence Brief. https://druglandscape.com/ci/leuprolide-oral-tablet-4-mg-bid. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab